ALINT IntegraGen SA

0.0823USD0.0750 EUR · EPA0.00%Mkt Cap: 539370 USDP/E: —

IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology an…

Key Statistics

Company
Market Cap539.37K USD
Enterprise Value682.18K USD
Revenue (TTM)4.66M USD
Gross Profit5.50M USD
Net Income (TTM)-187.99K USD
Revenue/Share0.71 USD
Last Price0.0823 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees27
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0010908723
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.26
EV/Revenue0.15
P/S0.12
P/B-0.25
EPS (TTM)-0.02 USD
EPS (Forward)—
52W Range
0.014318% of range0.3959
52W High0.3959 USD
52W Low0.0143 USD
Profitability
Gross Margin40.03%
Oper. Margin-56.27%
EBITDA Margin-55.51%
Profit Margin-1.37%
ROE-8.52%
ROA-2.14%
ROIC-30.25%
ROCE-4.13%
Growth
Revenue Growth-27.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.73M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt142.81K USD
Net Debt/EBITDA-0.06
Net Debt/FCF—
Balance Sheet
Debt/Equity0.56
Current Ratio0.43
Quick Ratio0.35
Book Value/Sh-0.33 USD
Cash/Share0.03 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.6.56M
Float—
Insiders65.90%
Institutions0.00%
Technical
SMA 500.0817 (+0.7%)
SMA 2000.1710 (-51.9%)
Beta0.60
S&P 52W Chg12.00%
Avg Vol (30d)96.56K
Avg Vol (10d)0
Technical Indicators
RSI (14)50.2
MACD-0.0001
MACD Signal-0.0011
MACD Hist.+0.0010
BB Upper0.1057 USD
BB Middle0.0836 USD
BB Lower0.0615 USD
BB Width52.91%
ATR (14)0.0076 USD
Vol Ratio (20d)0.00x

About IntegraGen (EPA: ALINT)

›

IntegraGen (EPA: ALINT) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 27 employees.

The shares were at 0.0750 EUR on 18 November 2026, down 42.3% over 52 weeks. Its 52-week range is 0.0130 EUR to 0.3610 EUR: the price is 79.2% below the high and 476.9% above the low.

Its market capitalisation is 491.77K EUR.

IntegraGen reports return on equity of -8.5%, an operating margin of -56.3% and revenue down 27.9% year over year.

Its debt exceeds its cash by 130.20K EUR, a debt-to-equity ratio of 0.56. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.